WHEN MASS GENERAL BRIGHAM announced two weeks ago that it would not offer a controversial new drug treatment for Alzheimer’s disease to patients, it was an important statement from the […]
WHEN MASS GENERAL BRIGHAM announced two weeks ago that it would not offer a controversial new drug treatment for Alzheimer’s disease to patients, it was an important statement from the […]